[go: up one dir, main page]

AR079876A1 - Gonadotrofina corionica humana recombinante con alto contenido de acido sialico y uso farmaceutico de la misma - Google Patents

Gonadotrofina corionica humana recombinante con alto contenido de acido sialico y uso farmaceutico de la misma

Info

Publication number
AR079876A1
AR079876A1 ARP100103608A ARP100103608A AR079876A1 AR 079876 A1 AR079876 A1 AR 079876A1 AR P100103608 A ARP100103608 A AR P100103608A AR P100103608 A ARP100103608 A AR P100103608A AR 079876 A1 AR079876 A1 AR 079876A1
Authority
AR
Argentina
Prior art keywords
sialic acid
gonadotrophine
same
recombinant human
high content
Prior art date
Application number
ARP100103608A
Other languages
English (en)
Original Assignee
Ferring Int Ct Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Int Ct Sa filed Critical Ferring Int Ct Sa
Publication of AR079876A1 publication Critical patent/AR079876A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

El uso de la rhCG recombinante en el tratamiento de la infertilidad. Reivindicacion 1: hCG recombinante (rhCG) incluyendo la sialilacion de alfa2,3- y alfa2,6-. Reivindicacion 2: hCG recombinante en conformidad con la reivindicacion 1 con un contenido de ácido siálico [expresado en términos de relacion de moles de ácido siálico con moles de proteína] de 15 mol/mol o mayor. Reivindicacion 10: hCG recombinante en conformidad con cualquier reivindicacion anterior producida o expresada en una línea celular Per.C6, una línea celular derivada de Per.C6 o una línea celular modificada de Per.C6.
ARP100103608A 2009-10-05 2010-10-05 Gonadotrofina corionica humana recombinante con alto contenido de acido sialico y uso farmaceutico de la misma AR079876A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09252360 2009-10-05

Publications (1)

Publication Number Publication Date
AR079876A1 true AR079876A1 (es) 2012-02-29

Family

ID=41471027

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP100103608A AR079876A1 (es) 2009-10-05 2010-10-05 Gonadotrofina corionica humana recombinante con alto contenido de acido sialico y uso farmaceutico de la misma
ARP220101408A AR125991A2 (es) 2009-10-05 2022-05-27 Preparación farmacéutica

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP220101408A AR125991A2 (es) 2009-10-05 2022-05-27 Preparación farmacéutica

Country Status (25)

Country Link
US (5) US8975226B2 (es)
EP (2) EP2486051B1 (es)
JP (6) JP6176924B2 (es)
KR (7) KR20210014767A (es)
CN (1) CN107050434B (es)
AR (2) AR079876A1 (es)
AU (1) AU2010304922B2 (es)
BR (1) BR112012007990A2 (es)
CA (1) CA2776790A1 (es)
DK (1) DK2486051T3 (es)
ES (2) ES2798258T3 (es)
HR (1) HRP20200941T1 (es)
HU (1) HUE050793T2 (es)
IL (3) IL218548A (es)
IN (1) IN2012DN02073A (es)
JO (1) JOP20200039A1 (es)
LT (1) LT2486051T (es)
MX (1) MX2012003951A (es)
PL (1) PL2486051T3 (es)
PT (1) PT2486051T (es)
RS (1) RS60413B1 (es)
RU (2) RU2724528C2 (es)
SI (1) SI2486051T1 (es)
TW (2) TWI532495B (es)
WO (1) WO2011042688A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2691119B1 (en) * 2011-03-31 2018-08-01 Ferring B.V. Pharmaceutical preparation
WO2012168680A1 (en) * 2011-06-06 2012-12-13 Ferring B.V. Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
WO2013093760A2 (en) * 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
EP2930241B1 (en) 2012-12-10 2019-06-26 Seikagaku Corporation Novel recombinant factor c and method for producing same, and method for measuring endotoxin
JP2018500934A (ja) * 2014-12-22 2018-01-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｍｐ依存性シアリダーゼ活性
MX389908B (es) 2015-04-24 2025-03-20 Ferring Bv Metodo de produccion de gonadotrofina.
MX381279B (es) 2015-06-26 2025-03-12 Ferring Bv Métodos de purificación y/o inactivación viral.
EP4534145A3 (en) 2018-04-30 2025-07-02 Ferring B.V. Composition for controlled ovarian stimulation
WO2021156720A1 (en) * 2020-02-05 2021-08-12 Novartis Ag Cho cell expressing il-15 heterodimers
CN116199742B (zh) * 2022-07-06 2025-01-24 华兰基因工程有限公司 一种重组人绒毛膜促性腺激素Fc融合蛋白制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4840896A (en) * 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
DK49987A (da) 1987-01-30 1988-07-31 Nordisk Gentofte Fremgangsmaade til behandling af infertilitet og middel til anvendelse ved fremgangsmaaden
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
PT814841E (pt) * 1995-03-21 2002-03-28 Applied Research Systems Formulacoes liquidas de hcg
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
KR100706469B1 (ko) 1997-06-25 2007-04-10 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 이황화결합으로 연결된 당단백질 호르몬 유사체, 이의제조방법 및 이의 용도
US6500627B1 (en) * 1998-02-03 2002-12-31 The Trustees Of Columbia University In The City Of New York Methods for predicting pregnancy outcome in a subject by HCG assay
US7304031B2 (en) * 2001-10-29 2007-12-04 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
WO2003050286A1 (en) * 2001-10-29 2003-06-19 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
WO2000067778A1 (en) 1999-05-07 2000-11-16 Applied Research Systems Ars Holding N.V. Gonadotrophins
EP1257564B1 (en) * 2000-02-22 2008-08-27 Laboratoires Serono SA Process for purification of recombinant hcg having a specific bioactivity
EP1425032A2 (en) 2001-09-12 2004-06-09 Applied Research Systems ARS Holding N.V. USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION
ATE329930T1 (de) 2001-10-22 2006-07-15 Applied Research Systems Fsh-zusammensetzungen mit hohem sialylierungsgrad und deren verwendung zur herstellung von arzneimitteln
CN1374525A (zh) * 2001-12-31 2002-10-16 陕西超英生物医学研究开发有限公司 一种抗体芯片、其制备技术及其检测方法
WO2004087211A2 (en) 2003-04-01 2004-10-14 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
EP2338333B1 (en) * 2003-04-09 2017-09-06 ratiopharm GmbH Glycopegylation methods and proteins/peptides produced by the methods
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
JP4518464B2 (ja) 2003-06-30 2010-08-04 ミヨシ油脂株式会社 紙類処理剤及び紙類
PL1654353T3 (pl) * 2003-08-18 2013-11-29 Glycotope Gmbh Nowotworowe linie komórkowe NM-F9 (DSM ACC2606) i NM-D4 (DSM ACC2605) oraz ich zastosowanie
WO2005076013A2 (en) * 2004-02-04 2005-08-18 Centre National De La Recherche Scientifique Process for screening glycoform-specific antibodies
CN1926242B (zh) * 2004-02-13 2013-01-16 格莱克托普有限公司 高活性糖蛋白加工条件及其有效生产方法
CN101137396A (zh) * 2005-03-11 2008-03-05 弗雷泽纽斯卡比德国有限公司 由无活性初始材料制备生物活性糖蛋白
DE112006002122B4 (de) * 2005-08-15 2016-09-22 Continental Automotive Systems, Inc. ( n. d. Ges. d. Staates Delaware ) Dieselabgas-Kohlenwasserstoff-Dosierventil für Fahrzeuge
RU2309411C2 (ru) * 2005-11-24 2007-10-27 Ростовский НИИ акушерства и педиатрии МЗ РФ Способ отбора пациенток с синдромом "пустых" фолликулов для проведения программы эко и пэ донорскими ооцитами
KR100809945B1 (ko) * 2006-02-01 2008-03-05 대한민국 인체장내정상세균총 특이반응 ｄｎａ칩 및 이를 이용한인체장내정상세균총의 변화에 의한 인체 위해성의 평가방법
US20080280818A1 (en) * 2006-07-21 2008-11-13 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
WO2008057683A2 (en) * 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2691119B1 (en) * 2011-03-31 2018-08-01 Ferring B.V. Pharmaceutical preparation
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض

Also Published As

Publication number Publication date
JP6580104B2 (ja) 2019-09-25
US9676835B2 (en) 2017-06-13
RS60413B1 (sr) 2020-07-31
CA2776790A1 (en) 2011-04-14
JP2021176867A (ja) 2021-11-11
JP7292153B2 (ja) 2023-06-16
US11292824B2 (en) 2022-04-05
JP6310440B2 (ja) 2018-04-11
IL218548A0 (en) 2012-05-31
CN102549011A (zh) 2012-07-04
HUE050793T2 (hu) 2021-01-28
AR125991A2 (es) 2023-08-30
EP3611185A1 (en) 2020-02-19
AU2010304922B2 (en) 2014-11-06
IL267556A (en) 2019-08-29
JP2018076296A (ja) 2018-05-17
JP2023075144A (ja) 2023-05-30
SI2486051T1 (sl) 2020-08-31
US20220340634A1 (en) 2022-10-27
ES3036152T3 (en) 2025-09-15
JP6176924B2 (ja) 2017-08-09
JP2016074680A (ja) 2016-05-12
US12234272B2 (en) 2025-02-25
PL2486051T3 (pl) 2020-09-07
TW201632198A (zh) 2016-09-16
TWI532495B (zh) 2016-05-11
HRP20200941T1 (hr) 2020-09-18
RU2016118236A3 (es) 2019-09-18
KR102489143B1 (ko) 2023-01-13
MX2012003951A (es) 2012-05-29
JOP20200039A1 (ar) 2022-10-30
WO2011042688A1 (en) 2011-04-14
IN2012DN02073A (es) 2015-08-21
EP3611185B1 (en) 2025-04-30
TW201113030A (en) 2011-04-16
KR20210014767A (ko) 2021-02-09
KR20120094909A (ko) 2012-08-27
TWI604850B (zh) 2017-11-11
PT2486051T (pt) 2020-06-17
LT2486051T (lt) 2020-07-10
IL250733A0 (en) 2017-04-30
DK2486051T3 (da) 2020-06-22
KR101804479B1 (ko) 2017-12-05
EP2486051B1 (en) 2020-03-25
JP2013506708A (ja) 2013-02-28
RU2724528C2 (ru) 2020-06-23
CN107050434B (zh) 2021-07-27
KR20170133531A (ko) 2017-12-05
AU2010304922A1 (en) 2012-03-29
US20130023476A1 (en) 2013-01-24
US20180030107A1 (en) 2018-02-01
IL218548A (en) 2017-03-30
RU2016118236A (ru) 2018-10-29
KR20210141771A (ko) 2021-11-23
ES2798258T3 (es) 2020-12-10
US20140249082A1 (en) 2014-09-04
US20200247863A1 (en) 2020-08-06
RU2588650C2 (ru) 2016-07-10
KR102213154B1 (ko) 2021-02-05
RU2012112907A (ru) 2013-11-10
KR20230012104A (ko) 2023-01-25
KR101987982B1 (ko) 2019-06-11
EP2486051A1 (en) 2012-08-15
US10526390B2 (en) 2020-01-07
US8975226B2 (en) 2015-03-10
JP2020000246A (ja) 2020-01-09
KR20190028823A (ko) 2019-03-19
IL250733B (en) 2019-07-31
CN107050434A (zh) 2017-08-18
BR112012007990A2 (pt) 2017-07-25
JP7196244B2 (ja) 2022-12-26
KR20190067256A (ko) 2019-06-14

Similar Documents

Publication Publication Date Title
AR079876A1 (es) Gonadotrofina corionica humana recombinante con alto contenido de acido sialico y uso farmaceutico de la misma
EA201170879A1 (ru) Полипептиды с ксиланазной активностью
Cole hCG, five independent molecules
TN2012000478A1 (en) Long - acting formulations of insulins
NZ596849A (en) Serum amyloid p derivatives and their preparation and use
AR071479A1 (es) Hormona foliculo estimulante recombinante (rfsh) con union de acido sialico en a2,3 y a2,6
NZ607069A (en) Modified relaxin polypeptides and their uses
SG178797A1 (en) Oligosaccharide chain added glp-1 peptide
PH12012502018A1 (en) Peptide for improving biostability of bioactive substance, and bioactive substance having improved biostability
NZ604877A (en) Improved recombinant human follicle-stimulating hormone
BRPI0917535A8 (pt) uso de insulina de ação ultra rápida
NZ600709A (en) Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
WO2012103496A3 (en) Expression of soluble viral fusion glycoproteins in mammalian cells
RU2013134126A (ru) Способ снижения уровня с-концевого телопептида коллагена 2 типа
NZ602702A (en) Modified fgf-21 polypeptides and their uses
MY181626A (en) Treatment of diabetes mellitus by long-acting formulations of insulins
MX352796B (es) Proteina de fusion anticancerigena.
MX344815B (es) Metodo para purificar el factor estimulante de colonias de granulocitos humano a partir de e. coli recombinante.
CL2012001656A1 (es) Polipéptido de somatotropina bovina que comprende uno o mas aminoácidos no naturales y que estan ligados a un polimero soluble en agua. composicion farmaceutica que comprende dichos polipeptidos.
MY169650A (en) Crystalline recombinant interferon with altered spatial configuration,three-dimensional structure and uses thereof
NZ590469A (en) Treatment of rheumatoid arthritis with human beta defensins (1-4)
BR112013032088A2 (pt) "polipeptídeo, composição farmacêutica e seu uso"
BR112015024609A2 (pt) proteína tendo atividade de xilose isomerase e utilização da mesma
BR112012026999A2 (pt) peptídeo de caseína para uso no tratamento de infecções uterinas.
DK2076532T3 (da) Cytokinderivater

Legal Events

Date Code Title Description
FC Refusal